Please login to the form below

Not currently logged in
Email:
Password:

Affymax

This page shows the latest Affymax news and features for those working in and with pharma, biotech and healthcare.

Omontys terminal as Takeda switches off support

Omontys terminal as Takeda switches off support

As a result, Takeda says it will now withdraw its US marketing application for Omontys, as Affymax has indicated it would not take over rights to the drug. ... For Affymax, taking over Omontys was never a realistic option, even if Takeda had found a

Latest news

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Furthermore, earlier this year the company withdrew its marketing authorization application (MAA) in Europe for the Affymax-partnered anaemia treatment Omontys (peginesatide) and recalled all lots of the drug in the

  • Affymax in a tailspin after Omontys recall Affymax in a tailspin after Omontys recall

    Makes heavy job cuts in face of bankruptcy threat. Affymax is slashing three quarters of its workforce and could be facing bankruptcy in the wake of the recall last month of ... Analysts put the chances of Omontys returning to the market as slim, noting

  • Takeda-Affymax recall Omontys in US after deaths Takeda-Affymax recall Omontys in US after deaths

    Several deaths related to the kidney disease treatment Omontys have led to a recall of the injection in the US by Takeda and Affymax. ... The recall is voluntary at the moment, with Takeda and Affymax working with the US FDA.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest appointments

  • KaloBios names Herb Cross as CFO KaloBios names Herb Cross as CFO

    He joins from Affymax. Herb Cross is to join KaloBios as the company's new chief financial officer. ... Cross joins from biopharma company Affymax, where he was also chief financial officer.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    During his time at Affymax, Dr Polu headed several areas, including clinical sciences, clinical operations and drug safety/pharmacovigilance. ... Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics